Latest Breaking News On - Structural heart disease - Page 1 : comparemela.com

Edwards Lifesciences Q1 Earnings: Mixed Results with Adjusted EPS Beating Estimates

Insights into Edwards Lifesciences' Financial Performance and Strategic Highlights

In small aortic annuli, self-expanding TAVR valve may be preferred for hemodynamics

Abbott Receives FDA Approval for TriClip™, First-of-its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's first-of-its-kind TriClip™ transcatheter edge-to-edge repair (TEER) system that's specifically designed for the treatment of tricuspid regurgitation (TR), or a leaky tricuspid valve. This approval follows .

FDA Approves TriClip TEER System for Tricuspid Regurgitation

Less than 2 months after being the subject of an FDA AdComm meeting, Abbott's TriClip TEER System has received approval for tricuspid regurgitation.

Peerbridge Health's Remote Device for Early Detection of Heart Failure Achieves 95.7% Success Rate in Trial

/PRNewswire/ Peerbridge Health, developer of a hospital-grade, remote diagnostic platform that harnesses AI to detect early signs of heart failure, today.